



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

**Oversight Committee Meeting
February 15, 2017**

1. Call to Order

A quorum being present, Presiding Officer Geren called the Oversight Committee to order at 11:03 a.m.

2. Roll Call/Excused Absences

Committee Members Present:

Angelos Angelou

Pete Geren

Donald (Dee) Margo

Amy Mitchell

Bill Rice, M.D.

Craig Rosenfeld, M.D.

Ned Holmes

~~Cynthia Mulrow, M.D.~~ 

Will Montgomery

3. Adoption of Minutes from November 17, 2016 meeting

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the minutes of the Oversight Committee meeting November 17, 2106.

4. Public Comment

Presiding Officer Geren noted that Susan Dawson, a leader in the education reform community, had made a request for public comment. Ms. Dawson stated that CPRIT investments into preventing cancer could have a much greater impact if made in a way that more effectively leveraged the collective impact of multiple institutions in cancer research, treatment and prevention. Her suggestions included:

- Target grants/investments to focus on collaborative efforts of institutions (public and private) working together (not just multi-investigators)
- Target specific highly prevalent/low treatment efficacy cancer types as a platform for collaboration

There were no other requests for public comment.

5. Grantee Presentations

Presiding Officer Geren called on Dr. Rebecca Garcia, Chief Prevention and Communications Officer, to introduce Keith Argenbright, MD, MMM, Director of the Moncrief Cancer Center in Ft. Worth, part of The University of Texas Southwestern (UT Southwestern), Chief of the Division of Community Health Sciences at UT Southwestern, and a professor at the Harold C. Simmons Comprehensive Cancer Center.

Dr. Argenbright reported that the Moncrief Cancer Center provides education, early detection, patient navigation, and survivorship services to the medically underserved in 35 north Texas counties. The total population of underserved in those counties is estimated to be 3.45 million, and the Moncrief Cancer Center projects they will serve 1.29 million of that population with breast, cervical, and colorectal cancer screenings and patient navigation. Dr. Argenbright stated that the \$800,000 CPRIT survivorship grant enabled the program to apply for and receive a federal grant valued at \$21 million, which means they attracted about \$26 for every dollar that CPRIT invested in that program.

The program provides cancer survivorship services to approximately 15,000 patients. Their services have resulted in a 31% increase in breast cancer screenings, 28% increase in colorectal screenings and a 17% aggregate increase in quality of life among survivors. Additionally, the program has a first-of-its-kind mobile clinic targeting underserved rural communities. The mobile clinic has 3-D mammography, telemedicine, an exercise area, nutrition education, consultation rooms, cervical screenings, and phlebotomy services. Dr. Argenbright stated that without CPRIT funding (over \$17 million in multiple grants), the Moncrief Cancer Center would not be able to reach such a large service area.

An Oversight Committee member asked Dr. Argenbright about the number of men versus women served and whether the project provides lung cancer screenings. He responded that breast cancer is primarily, though not exclusively, a female cancer and that cervical cancer is only a female cancer. Colorectal screenings are divided evenly between men and women. Lung cancer screening is a relatively new screening and the program is contemplating a lung screening program. Additionally, the Moncrief Center held a prostate cancer awareness and education event.

In response to a question about how the “increase in quality of life” is measured, Dr. Argenbright stated that a survey is administered to patients when they enter the program and then again periodically throughout their time in the program. The 17% increase was statistically significant.

An Oversight Committee member asked why the program made the investment into a mobile clinic for screening. Dr. Argenbright discussed the difficulties rural residents encounter when having to miss work to drive hours into Ft. Worth for screening. Also, because trust often must be established with populations before they will accept the program’s services, the mobile unit makes repeat trips to develop relationships with the rural communities.

Presiding Officer Geren called on Mr. Michael Lang, Chief Product Development Officer, to introduce the next grantee. Mr. Lang introduced Dr. Eric Poma, Founder and Chief Executive Officer, Chief Scientific Officer, and Director of Molecular Templates, Inc., with a doctorate degree in molecular biology and immunology and a master of business degree in finance. Molecular Templates is a biopharmaceutical company that has received multiple CPRIT grants.

Dr. Poma gave an overview of the drugs Molecular Templates is developing and the conduct of the clinical studies. He founded the company in 2009 with the goal of engineering a new class of oncology drugs. The medical community has largely optimized the benefits of chemotherapy and the genetic instability of cancer requires new ways of attacking tumor cells. Molecular Templates is having good success with treatment of elderly patients and patients who have failed or been unable to tolerate conventional treatment. He reports that the company would not have been able to reach this stage of clinical studies without CPRIT funding.

Presiding Officer Geren thanked the grantees for their work and for taking the time to make presentations to the Oversight Committee.

13. Internal Auditor Report

Presiding Officer announced that Agenda Item 13 – Internal Auditor Report would be taken up next out of agenda order.

Ms. Alyssa Martin, Internal Auditor, presented updates on the status of the 2017 Internal Audit Plan and Schedule, including the status of the internal audit of CPRIT training programs. There were no questions for Ms. Martin.

14. Advisory Committee on Childhood Cancer

Presiding Officer announced that Agenda Item 14 would be taken up next out of agenda order.

Dr. Willson introduced Dr. Susan Blaney, Chair of the Advisory Committee on Childhood Cancers (ACCC), to present the committee's annual report. He noted that Dr. Blaney is Deputy Director of the Texas Children's Cancer and Hematology Centers and Executive Vice Chair the Department of Pediatrics at Baylor College of Medicine.

Dr. Blaney reported that CPRIT expanded the committee recently to include representation of areas outside of the universities. She stated the success of CPRIT research applications focused on childhood cancers has continued to increase due in large part to focused RFA mechanisms resulting in the funding of more than 30 childhood and adolescent cancer research projects to date, an increase in the number of grant awards from 4% in 2014 to 16.7% in 2016. She noted that CPRIT-funded investigators have been able to garner an additional \$17.5 million in follow-along funding. ACCC recommendations include:

- Issue RFAs for individual investigator grants specific to childhood and adolescent cancer on a continuous basis
- Release a RFA for multi-investigator research awards focused on childhood and adolescent cancer (with an emphasis on inter-institutional collaboration)
- Increase in the number of pediatric oncologists and laboratory investigators studying childhood cancer who serve on CPRIT grant review panels
- Consider setting aside at least one recruitment grant for pediatric oncology for each recruitment RFA
- Consider prioritizing recruitment of suitable candidates to underserved areas of Texas when appropriate research or clinical resources are available in those areas
- Continuation of the opportunity for institutions to submit an application for a shared resource to support research directed toward childhood and adolescent cancer in addition to an application to support another area of research
- Consider developing a grant funding mechanism to support the development of high-impact, multi-institutional shared resources that focus on childhood cancer
- Consider supporting childhood cancer research in Texas such as preclinical drug testing and/or model development cores, research or clinical (CLIA-certified) sequencing cores that define the genomic alterations in childhood cancers to more rapidly advance the field of precision medicine in pediatric oncology
- Explore innovative ways to facilitate and encourage commercial development of drugs and diagnostics for childhood cancer

15. University Advisory Committee – Annual Report

Presiding Officer announced that Agenda Item 15 would be taken up next out of agenda order.

Dr. Willson introduced Dr. Mary Ann Ottinger, Chair of the University Advisory Committee (UAC). Dr. Ottinger is Associate Vice Chancellor at the University of Houston System and Associate Vice President of Research at the University of Houston. Dr. Willson stated that the University Advisory Committee (UAC) meets quarterly with CPRIT staff. CPRIT staff consults the UAC before bringing project priority recommendations to the Oversight Committee.

As UAC chair, Dr. Ottinger presented the committee's annual report. She stated that the UAC members feel CPRIT is a critical catalyst, providing a focus on 1) understanding the underlying mechanisms and triggers that stimulate the onset and progression of cancer and cancer-related disease; 2) the efficacy of interventions; and 3) the testing of highly promising technologies and products. The committee feels recruitment grants continue to be highly effective in attracting talented cancer researchers to Texas institutions and they appreciate the interactive approach of the CPRIT staff with the cancer research community. UAC recommendations include:

- Consider funding programs that provide support for innovative clinical trials that incorporate translational studies involving biological/molecular correlates.

- Promote greater linkage between the Product Development Program and the research community, thereby enhancing the effectiveness of the Early Translational Research Awards.
- Monitor outcomes from Early Translational Research Programs, which are predicted to have high potential for impact.

In response to questions about the amount of paperwork required for CPRIT grants, Dr. Ottinger stated that a National Academy study showed that an investigator spends 42% of his or her time on administration, so anything to reduce paperwork allows more time for research. When asked if the UAC had any recommendations on how to streamline CPRIT's required paperwork, she stated the UAC would develop some recommendations during the coming year at the Oversight Committee's request.

7. Chief Compliance Officer Report

Presiding Officer announced that Agenda Item 7 would be taken up next out of agenda order.

Mr. Burgess presented the Chief Compliance Officer report on compliance activities over the last quarter.

Mr. Burgess highlighted the following activities:

Training & Support

CPRIT Oversight Committee members and CPRIT staff completed ethics and compliance training that was provided through an on-line module. Training covered the agency's Code of Conduct and Ethics, Conflict of Interest Policy, Non-Disclosure Agreement, and other required statements and certifications.

CPRIT has scheduled a grantee training webinar for March 9. The training fulfills an annual compliance training requirement for grantees' Authorized Signing Officials and other grantee staff. The training will focus on administrative rules changes, grantee reporting requirements, compliance program activities, and the grant closeout process.

Mr. Burgess reported the following compliance activities that support the integrity and transparency of CPRIT's agency processes.

- FSR Reviews – 132 second-level reviews of grantee Financial Status Reports (FSRs) were performed during the month of January, of which 13 (10%) required resubmission due to insufficient or inaccurate documentation.
- Desk Reviews and On-site Reviews – 11 desk reviews and 2 on-site reviews were performed during the month of January.
- Annual Compliance Attestation (Self-Certification) – staff is currently working with three grantees to remediate attestation findings.

Mr. Burgess clarified that the grantee risk assessment, which assesses financial exposure, entity maturity and prior experience, is used to determine whether a grantee will receive a desk review, on-site review, or other type of compliance monitoring.

There were no questions for Mr. Burgess.

10. Chief Product Development Officer Report

Presiding Officer announced that Agenda Item 10 would be taken up next out of agenda order.

Mr. Michael Lang, Chief Product Development Officer, reported on the review cycle status, noting that of the three companies selected for due diligence in the FY 2017 Cycle 1, the Product Development Review Council did not recommend any applications for funding. For the FY 2017 Cycle 2, peer review will take place between March and July of 2017. He will present any recommendations for Oversight Committee consideration at the August 2017 meeting.

- **Standard Revenue Sharing Terms**

Staff recommends a change to the standard revenue sharing terms for Product Development grants. The recommended change applies only to companies that are developing services, diagnostics, or devices. The standard revenue sharing terms for therapeutic companies receiving CPRIT grants remain the same as originally adopted in January 2015.

The proposed change modifies the standard revenue sharing royalty rate to 2.5%, decreasing to 0.5% once the grantee has made revenue sharing payments totaling 2.5X the grant amount. The royalty obligation ceases when the governmental grant of exclusivity (e.g. patents) expires.

The changed terms recognize the smaller profit margins for non-therapeutic companies. Revising the standard revenue sharing terms for services, diagnostics, and device firms may incentivize more companies to apply to CPRIT and diversify the Product Development portfolio.

- **Matching Requirements for Second Awards**

Staff recommends that the Oversight Committee approve a change to the required amount of matching funds for Product Development grantees who are receiving their second CPRIT award. Grantees are currently required to dedicate to the grant project \$1 of their own funds for every \$2 of CPRIT grant award funds. The recommended proposal increases the Product Development grantee's matching fund obligation to \$1 for every \$1 contributed by CPRIT if the grantee is receiving a second Product Development grant.

Presiding Officer Geren asked the Chair of the Product Development Subcommittee to speak to the proposals for revenue sharing terms and matching requirements for second awards. Dr. Rosenfeld stated the subcommittee had considered both changes and recommended approval by the full Oversight Committee.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Holmes, the Oversight Committee unanimously voted to approve the recommended new revenue sharing terms for devices, diagnostics, services and other programs.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Holmes, the Oversight Committee unanimously voted to approve the recommended policy for increased matching fund requirements for Product Development grantees receiving a second Product Development grant.

Agenda Items 10, 19, 20

Presiding Officer Geren invoked Texas Open Meetings Act Section 551.071 and Health and Safety Code Section 102.2631 to move the Oversight Committee into closed session to take up Agenda Items 10, 19, and 20. Mr. Geren asked CPRIT staff Wayne Roberts (Chief Executive Officer), Kristen Doyle (Deputy Executive Officer and General Counsel), Michael Lang (Chief Product Development Research Officer), and Vince Burgess (Chief Compliance Officer) to join the Oversight Committee in the closed session.

Presiding Officer Geren convened the closed session at 12:55 p.m.

Presiding Officer Geren reconvened the open meeting at 2:49 p.m.

10. Chief Product Development Officer Report (continued)

Presiding Officer Geren called on Mr. Lang to present contract amendments for RP110508 and DP160057, awards to Bellicum Pharmaceuticals.

Mr. Lang reported that CPRIT awarded Bellicum contract RP110508 under revenue sharing terms in effect at the time of the award. CPRIT approved the award for DP160057 recently under current revenue sharing terms. For the convenience of both the company and CPRIT, the contract amendments would aggregate the total amount of both awards into the contract and apply current standard revenue sharing terms.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the recommended amendments for the Bellicum contracts RP110508 and DP160057 as presented by Mr. Lang.

Mr. Lang presented the contract amendment to CP120038 to Fujifilm Diosynth Biotechnologies (Fujifilm) for Oversight Committee approval. He explained that CPRIT made an award originally to a spinout from Texas A&M University called Kalon Biotherapeutics, a contract manufacturer of specialty pharmaceuticals. Since then, Fujifilm, a much larger international firm, acquired Kalon. The original award did not contain a royalty repayment because of the nature of the contract manufacturer, providing instead for payment through discounts offered to CPRIT awardees at Texas institutions. This process has not worked well for the parties. The proposed change requires the company to pay royalties, which CPRIT will credit differentially when earned from Texas institutions versus non-Texas institutions. This provides a return to CPRIT similar to the current standard structure of royalty-based returns, but incentivizes the company to continue to work with Texas institutions.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the recommended contract amendment for CP120038, Fujifilm Diosynth Biotechnologies as presented by Mr. Lang.

Presiding Officer Geren stated that the Oversight Committee would take no further action at this time on items discussed in closed session.

6. Chief Executive Officer Report

Wayne Roberts, Chief Executive Officer, presented his report including:

- The Senate Finance Committee budget held a hearing on February 1, 2017 related to CPRIT. CPRIT's budget hearing with the House Appropriations Subcommittee on Article I is scheduled for February 22, 2017.

At the request of Presiding Officer Geren, a letter to the Legislative Leadership has been prepared for Oversight Committee consideration and signature during this meeting, which would add emphasis to CPRIT's budget request. Mr. Geren reported that CPRIT circulated the letter to Oversight Committee members at their desks. There were no questions from the Oversight Committee members.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve and sign the letter to legislative leadership showing support for CPRIT's legislative appropriations requested rider changes to enhance operational efficiencies and maximize available funds.

- Mr. Roberts stated the Sunset bills have been referred to committees in the House and Senate to extend CPRIT's sunset date from 2021 to 2023, along with the general operations bills that covers several topics. The most important element is giving CPRIT the ability to work with the Texas Treasury Safekeeping Trust Company.

- The American Cancer Society released the results of a poll in January related to CPRIT and cancer research. The poll indicates that 74% of the public believes that it is more important to fund cancer research through an entity such as CPRIT than to not spend the money.
- On February 7, 2017, the Texas Health Care and Biosciences Institute had its annual summit. One of the Institute's legislative priorities is to support CPRIT's legislative funding and agenda. On February 8, a number of the Institute's members visited legislators at the Capitol about a number of issues including support for CPRIT.
- CPRIT has three grant accountant vacancies, which are affected by Governor Abbott's freeze on state agency hiring. Staff has submitted a request for an exemption from the freeze for these positions which were approved by the last legislature to address State Auditor findings from January 2013.
- CPRIT has completed the 2016 Annual Report and hard copies will be mailed to Oversight Committee members after printing.
- Sufficient funds are available for the awards being presented today. If the Oversight Committee approves all recommended awards, there will be a balance of \$143.2 million available for the May and August meetings.
- Staff has created a "Significance Report" from responses gathered from closed CPRIT grants to identify what each grantee studied, what was learned, and what is the significance of the work to the taxpayers of Texas. CPRIT will continuously update and post this document on the agency's website.

There were no questions for Mr. Roberts.

8. Chief Scientific Officer Report and Grant Award Recommendations

Dr. James Willson, Chief Scientific Officer, reported on the impact of CPRIT's recruitment program. This program is unique to Texas and is nationally recognized as making it possible to do things in Texas "that are difficult or impossible to do in most other places" (*The Texas Brain Gain, J Clin Invest. 2012;12:424*). Dr. Willson noted that of a total of 167 applications approved by the CPRIT Scientific Review Council, 74% have been accepted by the recruits.

Dr. Willson reported that CPRIT scholars include eight members of the National Academies of Science; Medicine, and Engineering; two members of the Howard Hughes Medical Institute; and two National Cancer Institute Outstanding Investigators. In addition to CPRIT funding, CPRIT Scholars received \$195 million in follow-on research funding awards in national peer reviewed grants.

Academic Research Grant Award Recommendations

Dr. Willson presented five awards totaling \$22,000,000 for Oversight Committee approval. He noted that the SRC approved application RR170007, Recruitment of Rising STAR Dr. Andrea Ventura, nominated by The University of Texas M.D. Anderson Cancer Center. Dr. Ventura declined the recruitment offer after the SRC made their recommendation.

Program Priorities Addressed:

Dr. Willson reported that all of the applications proposed to the Oversight Committee for funding this cycle address the Academic Research Program priority to recruit outstanding cancer researchers to Texas.

Academic Research Grant Award Recommendations

App ID	Candidate	Mech.	Organization	Budget
RR170013	Giuseppe Pelicci	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000
RR170011	Gerard Evan	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000
RR170008	Yair Reisner	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000
RR170010	Ram Madabhushi	RFTF M	The University of Texas Southwestern Medical Center	\$2,000,000
RR 170014	Han Xiao	RFTF M	Rice University	\$2,000,000

REI: Recruitment of Established Investigators

RRS: Recruitment of Rising Stars

RFTFM: Recruitment of First-Time Tenure Track Faculty Members

Compliance Certification

Mr. Vince Burgess, Chief Compliance Officer, presented his certification of the review process for the proposed grant awards recommended to the Oversight Committee at this meeting including Academic Research and Prevention awards. He stated he had reviewed the compliance pedigrees for the grant applications submitted to CPRIT for the following mechanisms:

- Recruitment of Established Investigators
- Recruitment of First-Time, Tenure-Track Faculty Members
- Competitive Continuation/Expansion for Evidenced-Based Cancer Prevention Services
- Evidence-Based Cancer Prevention Services
- Dissemination of CPRIT-Funded Cancer Control Interventions

Mr. Burgess stated that he had conferred with staff at CPRIT and SRA, International (SRA), CPRIT’s contracted third-party grants administrator, regarding academic research and

product development research awards and studied the supporting grant review documentation, including third-party observer reports for the peer review meetings.

Mr. Burgess reported that he was satisfied that the application review process that resulted in the Program Integration Committee's recommendations followed applicable laws and agency administrative rules. He certified the academic research and prevention award recommendations for the Oversight Committee's consideration.

Conflict of Interest Notification

Presiding Officer Geren noted for the record that no Oversight Committee member reported a conflict of interest with any recruitment application recommended for an award.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Holmes, the Oversight Committee unanimously voted to approve the Program Integration Committee's recommendations for recruitment awards.

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Mr. Montgomery, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff, and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

RP170259 Contract Amendment

Dr. Willson presented a proposed contract amendment for approval. He reported that he presented RP170259 to the Oversight Committee for approval in November 2016. The award approved by the Oversight Committee reflected the SRC's recommendations to reduce the number of Post-Doctoral trainees per year, to reduce the funding for the training program manager to 50% (from proposed 100% FTE), and to adjust the budget to reflect a reduction of 3 trainees per year. The award amount approved by the Oversight Committee on November 16, 2016, \$2,071,403, reflected the reductions and adjustments recommended by the SRC.

However, when calculating the revised award amount for Oversight Committee approval, CPRIT staff did not include fringe benefit costs for six Post-Doctoral trainees. Fringe benefits are an authorized expense that may be included in grantee budgets. The exclusion was an inadvertent oversight.

Dr. Willson requested Oversight Committee approval to increase the funding for RP170259 by \$576,748 to \$2,648,151 to correct this omission. The revised amount is less than the budget originally requested in the grant application, but more than the amount originally approved by the Oversight Committee in November.

Research Training Award Recommendation

ID	Title	PI	Organization	Current Award	Recommended Award
RP170259	CPRIT Cancer Prevention Research Training Program	Chang, Shine	The University of Texas M. D. Anderson Cancer Center	\$2,071,403	\$2,648,151

MOTION:

On a motion made by Dr. Rosenfeld and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the recommended modification to the total award amount for RP170259 to \$2,648,151, and to direct CPRIT staff to make the change to the award contract.

9. Chief Prevention and Communications Officer Report and Grant Award Recommendations

Presiding Officer Geren called Dr. Rebecca Garcia to report Communications and Prevention activities and to present the Prevention award recommendations.

Communications Report

Dr. Garcia reported on the Communications activities, including earned media, publicizing grant awards announcements, media coverage of CPRIT, ongoing projects, and events/meetings attended. She recognized Chris Cutrone for his work on CPRIT’s 2016 Annual Report and Spencer Miller-Payne for his work on the Significance Report.

Dr. Garcia stated that in addition to the activities reported in the Oversight Committee meeting materials, staff had scheduled press meetings with new reporters to brief them on the background of the agency and its programs. The intent of the meetings was to educate, but ultimately the meetings resulted in some positive articles written about CPRIT.

Additionally, she reported that Communications staff will be using the various cancer awareness months to highlight the work of various grantees throughout the state. For example, January was Cervical Cancer Awareness Month and CPRIT’s efforts resulted in seven broadcast stories and two online stories.

Prevention Program Report

Dr. Garcia presented an overview of the grant application cycle that produced the recommendations for consideration. She reported that five RFAs for Cycle 17.1 were released in May 2016. CPRIT received 36 applications. After administrative review, five were withdrawn and CPRIT assigned 31 applications requesting \$36,684,532 to the review panels. Two peer review panels met in December 2016 in Dallas. The Prevention Review

Council (PRC) conducted a programmatic review January 20 and forwarded their recommendations to the Program Integration Committee (PIC). The PIC met January 31 and submitted its recommendations to the Oversight Committee for consideration today.

Dr. Garcia noted that CPRIT released five RFAs on November 17. Submissions are due March 2 with peer review meetings taking place in June. She will present recommendations to the Oversight Committee in August 2017.

Dr. Garcia reported that she and Ms. Magid held a webinar on January 11, 2017, to present the FY 2017 Cycle 2 funding opportunities and answer questions regarding the RFAs. More than 120 people participated in the webinar.

Prevention Grant Award Recommendations

Dr. Garcia presented nine projects totaling \$12,024,696 for Oversight Committee consideration. The Program Integration Committee voted to defer one project, PP170037, until a future FY 2017 meeting, pending sufficient funding. Dr. Garcia presented the grant recommendations in three slates and noted the Prevention Program priorities addressed by the grant recommendations.

Number	Grant Type	Amount
5	Competitive Continuation/Expansion for Evidence-Based Cancer Prevention Services	\$ 7,486,073
3	Evidence-Based Cancer Prevention Services	\$ 4,238,623
1	Dissemination of CPRIT-Funded Cancer Control Interventions	\$ 300,000

<u>Number of Applications Addressing Priorities</u>	
6	Prioritize populations disproportionately affected by cancer incidence, mortality or cancer risk prevalence
5	Prioritize geographic areas of the state disproportionately affected by cancer incidence, mortality or cancer risk prevalence
9	Prioritize underserved populations

Prevention Grant Awards

App ID	Mech.	Application Title	PD	Organization	Rec Budget
PP170036	CCE	Expansion and Continuation of Web-based Clinical Decision Support to Disseminate Tailored Screening Recommendations for Survivors of Pediatric Cancers	Poplack, David G	Baylor College of Medicine	\$1,500,000
PP170046	EBP	Using social marketing and mobile school-based vaccination clinics to increase HPV vaccination uptake in high-risk geographic areas	Cuccaro, Paula	The University of Texas Health Science Center at Houston	\$1,499,969
PP170004	CCE	DE Casa 2: Cervical Cancer Prevention in El Paso and West Texas	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	\$1,499,993
PP170023	CCE	Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation	Basen-Engquist, Karen M	The University of Texas M. D. Anderson Cancer Center	\$1,494,530
PP170010	EBP	Cervical Cancer Screening and Patient Navigation (X-SPAN)	Argenbright, Keith E	The University of Texas Southwestern Medical Center	\$1,499,816
PP170012	CCE	Building Bridges: Cancer Prevention Education and Screening for Refugees	Raines-Milenkov, Amy L	University of North Texas Health Science Center at Fort Worth	\$1,491,550

App ID	Mech.	Application Title	PD	Organization	Rec Budget
PP170015	DI	Disseminating Evidence-Based Cancer Genomics Training to Community Health Workers	Chen, Lei-Shih	Texas A&M University	\$300,000
PP170042	EBP	University Health System Hepatitis Viral Infection and Systematic Treatment Program (HepVISTA)	Villarreal, Roberto	University Health System	\$1,238,838
PP170039	CCE	Nicotine Recovery Program (NRP)	Hollis, Gina	Mental Health Mental Retardation of Tarrant County	\$1,500,000

CCE = Competitive Continuation/Expansion for Evidence-Based Cancer Prevention Services

EBP = Evidence-Based Cancer Prevention Services

DI = Dissemination of CPRIT-Funded Cancer Control Interventions

Presiding Officer Geren noted there were no reported conflicts of interest and that Mr. Burgess had previously certified these awards when he certified the Academic Research awards.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Program Integration Committee's recommendations for Evidence Based Cancer Prevention Services, Competitive Continuation/Expansion-Evidence Based Cancer Prevention Services, and Dissemination of CPRIT-Funded Cancer Control Intervention awards.

MOTION:

On a motion made by Mr. Montgomery and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the delegation of contract negotiation authority to the Chief Executive Officer and CPRIT staff, and authorized the Chief Executive Officer to sign the contracts on behalf of CPRIT.

11. Scientific Research and Prevention Program Committee Appointments

Mr. Roberts presented recommended appointments to the Scientific Research and Prevention Programs Committee.

Product Development Research Review Panels

- Leila Alland, M.D.

Academic Research Peer Review Panels

- Jean-Perre Issa, M.D.

MOTION:

On a motion made by Mr. Holmes and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the Scientific Research and Product Development Program Committee appointments.

12. Advisory Committee on Childhood Cancers Appointments

Mr. Roberts presented recommended appointments to the Advisory Committee on Childhood Cancers.

- Mohamad Al-Rahawan, M.D., MPH
- James Amatruda, M.D., Ph.D.
- Greg Aune, M.D.
- Juan Carlos Bernini, M.D.
- Stan Goldman, M.D.
- Meaghan Granger, M.D.
- Virginia Harod, M.D.
- Lisa Hartman, M.D.
- Barkat Hooda, M.D.
- Julie Luke, CPNP
- Cindy Schwartz, M.D., MPH
- Sheila Thampi, M.D.

MOTION:

On a motion made by Mr. Holmes and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the nominations to the Advisory Committee on Childhood Cancers.

16. Amendments to 25 T.A.C. Chapters 701 and 703

Kristen Doyle, Deputy Executive Officer and General Counsel, presented the proposed administrative rule changes to Chapter 703 as originally considered at the November 2016 meeting. The first rule amendment, Section 703.13 (e), removes a reference to a superseded OMB Circular A-133. The second rule amendment, Section 703.25, explains that a request to carry forward unspent grant funds from one project year to the next requires CPRIT approval if the amount of unexpended budget line item balance is 25 percent or more of the line item amount for the year. After adoption, CPRIT will submit the proposed rule changes

to the Secretary of State. The rules are effective 20 days after submission.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Holmes, the Oversight Committee unanimously voted to approve the final order adopting rule changes to Texas Administrative Code Chapters 703.

Ms. Doyle then presented for Oversight Committee approval a request to publish proposed changes in the *Texas Register* for public comment as presented in the Oversight Committee meeting materials regarding Sections 701.3, 703.5, 703.6, 703.11, and 703.24. CPRIT will also announce the opportunity for public comment on the agency's website and via the CPRIT's electronic list serve. The proposed changes are to CPRIT's administrative rules setting policy guiding CPRIT's grant review and grant contracting processes. After the 30-day public comment period ends, legal staff will summarize all public comments for the Oversight Committee's consideration at the May 2017 meeting.

Ms. Doyle noted that staff withdrew the proposed change to Section 703.10. After internal discussion among all the CPRIT programs and with CPRIT Compliance staff, it was determined this change is not necessary since the information is available through CPRIT's Compliance Program.

MOTION:

On a motion made by Dr. Rice and seconded by Mr. Margo, the Oversight Committee unanimously voted to approve the publication of the proposed changes to Texas Administrative Code Chapters 701 and 703, with the exception of Section 703.10, for publication in the *Texas Register*.

17. Chief Operating Officer Report

Ms. Heidi McConnell, Chief Operating Officer, reported on the following items.

- FY 2017, Quarter 1 Operating Budget
CPRIT expended or obligated approximately \$600,000 for Indirect Administration and \$9.1 million for Grant Review and Award Operations. During the quarter, CPRIT collected \$15,862 in revenue sharing payments.
- FY 2017, Quarter 1 Performance Measure Report
CPRIT met or exceeded targets for its key prevention measures, but did not meet the performance target on the product development measure on company relocations to Texas because no companies relocated during the reporting period.
- Debt Issuance History
The Texas Public Finance Authority issued \$116.9 million in commercial paper notes on behalf of CPRIT since the beginning of FY 2017.
- Financial Audit for Year Ending August 31, 2016
The audit performed by McConnell & Jones, LLP, was completed on December 5, 2016, with no audit findings.

There were no questions for Ms. McConnell.

18. Subcommittee Business

Presiding Officer Geren reported that he made interim subcommittee appointments to fill vacancies due to Oversight Committee member Cynthia Mulrow's resignation in November 2016. He requested final approval by Oversight Committee of the following subcommittee assignments:

- Prevention Subcommittee – Amy Mitchell and Dee Margo, with Mr. Margo as chair
- Audit Subcommittee – Will Montgomery will take over as chair of the subcommittee with Mr. Margo remaining as a member

MOTION:

On a motion made by Mr. Holmes and seconded by Dr. Rice, the Oversight Committee unanimously voted to approve the appointment of Amy Mitchell and Dee Margo to the Prevention Subcommittee, and to confirm Dee Margo as chair of the Prevention Subcommittee and Will Montgomery as chair of the Audit Subcommittee.

19. Compliance Investigation Pursuant to Health & Safety Code § 102.2631

20. Consultation with General Counsel

Presiding Officer Geren reported that the Oversight Committee had already taken up Agenda Items 19 and 20 and no further action was necessary.

21. Future Meeting Dates and Agenda Items

Presiding Officer Geren announced the next regular Oversight Committee meeting for May 17, 2017, at 10:00 a.m.

22. Adjourn

MOTION:

There being no further business, the Oversight Committee unanimously approved a motion to adjourn made by Presiding Officer Geren and seconded by Dr. Rice.

Meeting adjourned at 3:57 p.m.

Ang M. Mitchell

Signature

5/17/17

Date



2/15/17
2/15/17 Amy M. Mitchell

CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 1, 2017

Dear Oversight Committee Members:

I am pleased to present the Program Integration Committee's (PIC) unanimous recommendations for funding 14 grant applications totaling \$34,024,696. The PIC recommendations for five academic research grant awards and nine prevention awards are attached.

Dr. Jim Willson, CPRIT's Chief Scientific Officer, and Dr. Becky Garcia, CPRIT's Chief Prevention Officer, have prepared overviews of the academic research and prevention slates to assist your evaluation of the recommended awards. The overviews are intended to provide a comprehensive summary with enough detail to understand the substance of the proposals and the reasons endorsing grant funding. In addition to the full overviews, all of the information considered by the Review Councils is available by clicking on the appropriate link in the portal. This information includes the application, peer reviewer critiques, and the CEO affidavit for each proposal.

The PIC used the award deferral process set by CPRIT administrative rule § 703.7(d) to defer the decision of one Competitive Continuation/Expansion Evidence-Based Cancer Prevention Services application until a future FY 2017 meeting. No Oversight Committee action is necessary at this time.

The approval of these grant recommendations is governed by a statutory process that requires two-thirds of the members present and voting to approve each recommendation. Vince Burgess, CPRIT's Chief Compliance Officer, will certify that the review process for the recommended grants followed CPRIT's award process prior to any Oversight Committee action.

The award recommendations will not be considered final until the Oversight Committee meeting on February 15, 2017. Consistent with the non-disclosure agreement that all Oversight Committee members have signed, the recommendations should be kept confidential and not be disclosed to anyone until the award list is publicly announced at the Oversight Committee meeting. I request that Oversight Committee members not print, email or save to your computer's hard drive any material on the portal. I appreciate your assistance in taking all necessary precautions to protect this information.

If you have any questions or would like more information on the review process or any of the projects recommended for an award, CPRIT's staff, including myself, Dr. Willson, and Dr. Garcia are always available. Please feel free to contact us directly should you have any questions. The programs that will be supported by the CPRIT awards are an important step in our efforts to mitigate the effects of cancer in Texas. Thank you for being part of this endeavor.

Sincerely,
Wayne R. Roberts
Chief Executive Officer

Academic Research Recruitment Grant Award Recommendations

Rank	App ID	Candidate	Mechanism	Organization	Budget	Overall Score
1	RR170013	Giuseppe Pelicci	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000	1.2
2	RR170011	Gerard Evan	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000	1.6
3	RR170008	Yair Reisner	REI	The University of Texas M.D. Anderson Cancer Center	\$6,000,000	1.8
4	RR170010	Ram Madabhushi	RFTFM	The University of Texas Southwestern Medical Center	\$2,000,000	2.0
5	RR 170014	Han Xiao	RFTFM	Rice University	\$2,000,000	2.0

REI: Recruitment of Established Investigators

RFTFM: Recruitment of First-Time Tenure Track Faculty Members

Prevention Grant Award Recommendations

App ID	Mech.	Application Title	PD	Organization	Score	Rank Order	Rec Budget
PP170036	CCE	Expansion and Continuation of Web-based Clinical Decision Support to Disseminate Tailored Screening Recommendations for Survivors of Pediatric Cancers	Poplack, David G	Baylor College of Medicine	1.3	1	\$ 1,500,000
PP170046	EBP	Using social marketing and mobile school-based vaccination clinics to increase HPV vaccination uptake in high-risk geographic areas	Cuccaro, Paula	The University of Texas Health Science Center at Houston	1.8	2	\$ 1,499,969
PP170004	CCE	DE Casa 2: Cervical Cancer Prevention in El Paso and West Texas	Shokar, Navkiran K	Texas Tech University Health Sciences Center at El Paso	2.1	3	\$ 1,499,993
PP170023	CCE	Active Living After Cancer: Combining a Physical Activity Program with Survivor Navigation	Basen-Engquist, Karen M	The University of Texas M. D. Anderson Cancer Center	2.1	4	\$ 1,494,530
PP170010	EBP	Cervical Cancer Screening and Patient Navigation (X-SPAN)	Argenbright, Keith E	The University of Texas Southwestern Medical Center	2.1	5	\$ 1,499,816
PP170012	CCE	Building Bridges: Cancer Prevention Education and Screening for Refugees	Raines-Milenkov, Amy L	University of North Texas Health Science Center at Fort Worth	2.3	6	\$ 1,491,550
PP170015	DI	Disseminating Evidence-Based Cancer Genomics Training to Community Health Workers	Chen, Lei-Shih	Texas A&M University	2.4	7	\$ 300,000
PP170042	EBP	University Health System Hepatitis Viral Infection and Systematic Treatment	Villarreal, Roberto	University Health System	2.5	8	\$ 1,238,838
PP170039	CCE	Nicotine Recovery Program (NRP)	Hollis, Gina	Mental Health Mental Retardation of Tarrant County	3.4	9	\$ 1,500,000

CCE: Competitive Continuation/Expansion-Evidence-Based Cancer Prevention Services
 DI: Dissemination of CPRIT-Funded Cancer Control Interventions
 EBP: Evidence-Based Cancer Prevention Services



CANCER PREVENTION & RESEARCH
INSTITUTE OF TEXAS

February 15, 2017

The Honorable Jane Nelson
Chair, Senate Committee on Finance

The Honorable John Zerwas
Chair, House Committee on Appropriations

Dear Senator Nelson and Representative Zerwas:

Thank you for the recommended appropriations and staffing levels for the Cancer Prevention and Research Institute of Texas (CPRIT) contained in the Senate and House budget proposals pending before the 85th Texas Legislature. We appreciate these introduced funding levels especially in light of your serious state budgetary constraints.

The Oversight Committee unanimously writes to support and emphasize three important non-monetary requests for CPRIT. None of these items adds cost to the pending budget bills but will enhance operational efficiencies and maximize funds available for merit-based peer reviewed cancer research and prevention awards. Each is summarized below.

Modify Agency Rider 5 to a Sum Certain

The rider requires CPRIT to transfer \$2,969,554 per year to the Department of State Health Services (DSHS) to pay for the Texas Cancer Registry. CPRIT's original request was to end this transfer and pay for the Registry with other state funds. However, in recognition of the state's tight budget constraints we modified the request to make this rider a sum certain for DSHS purposes. Since 2010 the Employees Retirement System has transferred over \$600,000 from CPRIT bond proceeds to pay DSHS's proportional share of health insurance retiree benefits pursuant to Article IX, Sec. 6.08, Benefits Paid Proportional by Fund. This transfer has not been transparent because the transfers have not been reflected in any agency budget. The transfer, estimated at \$130,000 per year, reduces bond funds for cancer research which is their primary legal purpose. The requested rider language is:

5. Transfer to Department of State Health Services for the Cancer Registry. Out of amounts appropriated above out of General Obligation Bond Proceeds to the Cancer Prevention and Research Institute of Texas is \$2,969,554 out of General Obligation Bond Proceeds each fiscal year of the 2018-19 biennium which shall be transferred to the Department of State Health Services in Strategy A.1.2, Health Registries, Information, and Vital Records, for administration of the Cancer Registry in accordance with the Texas Constitution, Article III, Section 67 and Health and Safety Code, Chapter 102 and for the proportional share of health insurance benefit costs associated with Department of State Health Services retirees withdrawn by the Employees Retirement System from Fund 7639, T.P.F.A. G.O. Commercial Paper Series A&B Cancer Project Fund.

Delete Current Rider 7 Mandating LBB Approval of Contracts

This requirement is redundant, time consuming and unnecessary. The Oversight Committee exercises strong fiduciary control through its two-step contract review process. All contracts exceeding \$100,000 must be scrutinized and recommended for approval by an audit subcommittee that meets at least quarterly. Contracts then must be approved in open meeting by the full Oversight Committee. No request for contract approval has been made to the LBB without undergoing this process. No request has ever been denied.

Delays due to the additional LBB approval requirement have affected the ability of the agency to respond quickly to evolving operational and grant review issues. As of this writing, in the current biennium six approvals have taken anywhere from 47 to 85 days, averaging 63 days. The contracts have all been for grant management services, grant compliance monitoring, and grant application regulatory due diligence—all absolutely critical to comply with strict statutory requirements for our sophisticated peer review and compliance monitoring system.

Often the issues necessitating a new contract or contract change requiring LBB approval occur suddenly and are not predictable. Compounded by the already lengthy process to comply with good contracting best practices and state requirements it is not possible to accommodate the additional LBB approval period into the planning process. As a result, the entire pre- and post-award grant management support processes have come within hours of shutting down. On one occasion, grant compliance monitoring had to be slowed due to lack of timely LBB approval.


Revise Current Rider 4 to Allow the CEO to Report Transfers Pursuant to Article IX, Section 14.01

Article IX, Section 14.01 authorizes other state agency administrators to transfer from one appropriation item to another appropriation item in an amount not to exceed 20 percent of the appropriation from which the transfer is made for the fiscal year. CPRIT's request is to provide this same authority and reporting requirement to our CEO. Any line item transfer would still have to be approved by the Oversight Committee using the same process outlined above for contract approvals.

We recognize the formidable task before you as you craft the state budget for 2018-19. Thank you for your service and thank you for considering these requests.




Preston "Pete" Geren
Presiding Officer



Will Montgomery,
Vice Presiding Officer




Angelos G. Angelou



Ned Holmes



Donald "Dee" Margo



Amy Mitchell



William Rice, M.D.



Craig S. Rosenfeld, M.D.

xc:

The Honorable Dan Patrick, Lieutenant Governor
The Honorable Joe Straus, Speaker of the House or Representatives
Members, Senate Committee on Finance
Members, House Committee on Appropriations
Mr. Mike Morrissey, Office of the Lieutenant Governor
Mr. Andrew Blifford, Office of the Speaker
Mr. Steven Albright, Budget Director, Office of the Governor